DOI QR코드

DOI QR Code

The Depression Predictors among Patients with Peg-interferon Treated Hepatitis C

페그-인터페론 치료를 받는 C형 간염 환자의 우울 예측요인

  • Received : 2013.10.30
  • Accepted : 2014.02.03
  • Published : 2014.04.30

Abstract

Purpose: This study was to identify factors predicting the occurrence of depression among patients with hepatitis C treated with Peg-interferon. Methods: The subjects were 134 patients treated with Peg-interferon after the diagnosis with hepatitis C at the D University Hospital and 3 hospitals located in Busan, South Korea. The predictors of depression were identified by measuring the general characteristics of the subjects and their disease-related characteristics, social support, sleep disorders, and degree of side effects by interferon. The data were analyzed with a t-test, ANOVA, and logistic regression using the SPSS/WIN 18.0 program. Results: Sixty-six point four percent of the subjects suffered from mild to more severe depression. Fatigue, hair loss, itching, and sleep disorders turned out to be significant predictors. In addition, the explanatory power of these variables for the occurrence of depression was 70%. Conclusion: Sleep disorders and drug side effects were determined to have significant influence on the development of depression in hepatitis C patients treated with Peg-interferon. Therefore, the development of nursing intervention programs aimed to prevent depression by effectively managing sleep disorders and side effects is mandated in future to help the given population.

Keywords

References

  1. Almeida, A. G., Guindalini, C., Batista-Neves, S., de Oliveira, I. R., Miranda-Scippa, A., & Qurantini, L. C. (2010). Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. General Hospital Psychiatry, 32, 401-405. http://dx.doi.org/10.1016/j.genhosppsych.2010.03.001
  2. Blasiole, J. A., Shinkunas, L., LaBrecque, D. R., Arnold, R. M., & Zickmund, S. L. (2006). Mental and physical symptoms associated with lower social support for patients with hepatitis C. World Journal of Gastroenterology, 12, 4665-4672.
  3. Bonaccorso, S., Marino, V., Biondi, M., Grimaldi, F., Ippoliti, F., & Maes, M. (2002). Depression induced by treatment with interferon-$\alpha$ in patients affected by hepatitis C virus. Journal of Affective Disorders, 72, 237-241. http://dx.doi.org/10.1016/S0165-0327 (02)00264-1
  4. Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2004). Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain, Behavior, and Immunity, 18, 205-213. http://dx.doi.org/10.1016/j.bbi.2003.11.004
  5. Carroll, V. K., & Rado, J. T. (2009). Is a medical illness causing your patient's depression?. Current psychiatry, 8 (8), 43-54.
  6. Cohen, S., & Hoverman, H. (1983). Positive events and social support as buffers of life change stress. Journal of Applied Social Psychology, 13, 99-125. https://doi.org/10.1111/j.1559-1816.1983.tb02325.x
  7. Evon, D. M., Ramcharran, D., Belle, S. H., Terrault, N. A., Fontana, R. J., Fried, M. W., et al. (2009). Prospective analysis of depression during Peginterferon and Ribavirin therapy of chronic hepatitis C: Results of the Virahep-C study. The American Journal of Gastroenterology, 104, 2949-2958. http://dx.doi.org/10.1038/ajg.2009.528
  8. Evon, D. M., Verma, A., Simpson, K., Galanko, J. A., Dougherty, K. A., & Fried, M. W. (2008). Psychiatric symptoms during interferon treatment for hepatitis C: Experiences from a tertiary care hepatology centre. Alimentary Pharmacology & Therapeutics, 27, 1071-1080. http://dx.doi.org/10.1111/j.1365-2036.2008.03640.x
  9. Franzen, P. L., Buysse, D. J., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2010). Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-$\alpha$ treatment. Psychiatry Research, 177 (1-2), 240-245. http://dx.doi.org/10.1016/j.psychres.2009.02.011
  10. Hoffman, S. (2003). Sleep in older adult: Implications for nurses. Geriatric Nursing, 24, 210-216. http://dx.doi.org/10.1016/S0197-4572 (03)00213-1
  11. Hwang, S. Y., Lee, H. J., Park, K. T., Kim, K. Y., Lee, S. M., Park, C. W., et al. (2007). Effectiveness and complications of combination therapy with interferon $\alpha$ and ribavirin in patients with chronic hepatitis C. Korean Journal of Gastroenterology, 49, 166-172.
  12. Kim, E. S. (2009). Association between sleep disturbance and depression among patients with brain injury. Unpublished master's thesis. Keimyung University, Daegu.
  13. Kim, K. T., Han, S. Y., Kim, J. H., Yoon, H. A., Bak, Y. H., Kim, M. J., et al. (2008). Clinical outcome of pegylated interferon and ribavirin therapy. The Korean Journal of Hepatology, 14 (1), 36-45. https://doi.org/10.3350/kjhep.2008.14.1.36
  14. Korea Centers for Disease Control & Prevention. (2012, March). Viral hepatitis surveillance system and statue of C hepatitis sentinel surveillance in Korea. Seoul: Author.
  15. Kwon, J. H., & Bae, S. H. (2008). Current status and clinical course of hepatitis C virus in Korea. The Korean Journal of Gastroenterology, 51, 360-367.
  16. Lee, H. M. (2008). A study on the fatigue, depression, and sleep disorder of hemodialysis patients. Unpublished master's thesis, Chonnam National University, Gwangju.
  17. Lee, Y. H., & Song, J. Y. (1991). A study of the reliability and the validity of the BDI, SDS, and MMPI-D scales. Korean Journal of Clinical Psychology, 10 (1), 98-113.
  18. Lotrich, F. E., Ferrell, R. E., Rabinovitz, M., & Pollock, B. G. (2008). Risk for depression during interferon-$\alpha$ treatment is affected by the serotonin transporter polymorphism. Biological Psychiatry, 65, 344-348. http://dx.doi.org/10.1016/j.biopsych.2008.08.009
  19. Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007). Depression following pegylated interferon-alpha: Characteristics and vulnerability. Journal of Psychosomatic Research, 63, 131-135. http://dx.doi.org/10.1016/j.jpsychores.2007.05.013
  20. Malik, U. R., Makower, D. F., & Wadler, S. (2001). Interferonmediated fatigue. Cancer, 92, 1664-1668. http://dx.doi.org/10.1002/1097-0142 (20010915)92:6+<1664::AID-CNCR1494>3.0.CO;2-9
  21. Oh, J. J., Song, M. S., & Kim, S. M. (1998). Development and validation of Korean sleep scale A. Journal of Korean Academy of Nursing, 28, 563-572. https://doi.org/10.4040/jkan.1998.28.3.563
  22. Raison, C. L., Rye, D. B., Woolwine, B. J., Vogt, G. J., Bautista, B. M., Spivey, J. R., et al. (2010). Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: Association with fatigue motor slowing, and increased evening cortisol. Biological Psychiatry, 68, 942-949. http://dx.doi.org/10.1016/j.biopsych.2010.04.019
  23. Schafer, A., Scheurlen, M., Seufert, J., Keicher, C., Weissbrich, B., Rieger, P., et al. (2010). Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression. Journal of Hepatology, 52 (1), 10-15. http://dx.doi.org/10.1016/j.jhep.2009.10.007
  24. Shepard, C. W., Finelli, L., & Alter, M. J. (2005). Global epidemiology of hepatitis C virus infection. The Lancet infectious Diseases, 5, 558-567. http://dx.doi.org/10.1016/S1473-3099 (05)70216-4
  25. Sohn, S. K. (2002). Relationship between fatigue and sleep quality in patients with cancer. Journal of Korean Academy of Adult Nursing, 14 (3), 378-389.
  26. Suh, M. J. (1990). A study on factors influencing the state of adaptation of the hemiplegic patients. Journal of Korean Academy of Nursing, 20 (1), 88-117.

Cited by

  1. Changes in Quality of Life of Chronic Hepatitis C Patients Participating in Clinical Trial vol.30, pp.5, 2018, https://doi.org/10.13000/JFMSE.2018.10.30.5.1725